Processa Pharmaceuticals, Inc. Operating Leases, Rent Expense
Processa Pharmaceuticals, Inc. (PCSA) reported Operating Leases, Rent Expense of $5.54 thousand for the 12-month period ending 2018-12-31, per its 10-K/A filed 2019-04-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseAndRentalExpense · last filed 2019-04-08
- Processa Pharmaceuticals, Inc. operating leases, rent expense for the quarter ending 2016-12-31 was $0.00, a 100.00% decline year-over-year.
- Processa Pharmaceuticals, Inc. operating leases, rent expense for the quarter ending 2016-09-30 was $0.00, a 100.00% decline year-over-year.
- Processa Pharmaceuticals, Inc. operating leases, rent expense for the quarter ending 2016-06-30 was $0.00, a 100.00% decline year-over-year.
- Processa Pharmaceuticals, Inc. operating leases, rent expense for the quarter ending 2016-03-31 was $2.25K, a 85.06% decline year-over-year.
- Processa Pharmaceuticals, Inc. operating leases, rent expense for fiscal 2018 was $5.54K.
- Processa Pharmaceuticals, Inc. operating leases, rent expense for fiscal 2016 was $2.25K, a 95.50% decline from fiscal 2015.
- Processa Pharmaceuticals, Inc. operating leases, rent expense for fiscal 2015 was $50.03K, a 10.24% decline from fiscal 2014.
- Processa Pharmaceuticals, Inc. operating leases, rent expense for fiscal 2014 was $55.74K, a 53.13% increase from fiscal 2013.
| Period end | Operating Leases, Rent Expense 0 month | Operating Leases, Rent Expense 3 month | Operating Leases, Rent Expense 3 month as first filed | Operating Leases, Rent Expense 6 month | Operating Leases, Rent Expense 9 month | Operating Leases, Rent Expense 12 month |
|---|---|---|---|---|---|---|
| 2018-12-31 | $5.54K 10-K/A · filed 2019-04-08 | |||||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-25 | $0.00 derived: sum of 2 quarters · filed 2017-09-25 | $0.00 derived: sum of 3 quarters · filed 2017-09-25 | $2.25K 10-K · filed 2017-09-25 | ||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-09-08 | $0.00 derived: sum of 2 quarters · filed 2017-09-08 | $2.25K 10-Q · filed 2017-09-08 | $41.27K derived: sum of 4 quarters · filed 2017-09-08 | ||
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-30 | $2.25K 10-Q · filed 2017-08-30 | $41.27K derived: sum of 3 quarters · filed 2017-08-30 | $52.28K derived: sum of 4 quarters · filed 2017-09-08 | ||
| 2016-03-31 | $2.25K 10-Q · filed 2017-08-07 | $41.27K derived: sum of 2 quarters · filed 2017-08-07 | $52.28K derived: sum of 3 quarters · filed 2017-09-08 | $67.79K derived: sum of 4 quarters · filed 2017-09-08 | ||
| 2015-12-31 | $39.02K derived: 10-K 6 month − 10-Q 3 month · filed 2017-06-19 | $50.03K 10-K · filed 2017-06-19 | $65.54K derived: sum of 3 quarters · filed 2017-09-08 | $50.03K 10-K · filed 2017-09-25 | ||
| 2015-09-30 | $11.02K 10-Q · filed 2017-09-08 | $26.53K derived: sum of 2 quarters · filed 2017-09-08 | $41.13K 10-Q · filed 2017-09-08 | $92.05K derived: sum of 4 quarters · filed 2017-09-08 | ||
| 2015-08-31 | $5.54K 10-K · filed 2018-04-16 | |||||
| 2015-06-30 | $15.51K 10-Q · filed 2017-08-30 | $15.06K 10-Q · filed 2015-08-19 | $30.11K 10-Q · filed 2017-08-30 | $81.03K derived: sum of 3 quarters · filed 2017-08-30 | $86.31K derived: sum of 4 quarters · filed 2017-08-30 | |
| 2015-03-31 | $15.06K 10-Q · filed 2017-08-07 | $65.52K derived: sum of 2 quarters · filed 2017-08-07 | $70.80K derived: sum of 3 quarters · filed 2017-08-07 | $90.11K derived: sum of 4 quarters · filed 2017-08-07 | ||
| 2014-12-31 | $50.46K derived: 10-K 6 month − 10-Q 3 month · filed 2017-06-19 | $55.74K 10-K · filed 2017-06-19 | $75.05K derived: sum of 3 quarters · filed 2017-06-19 | $55.74K 10-K · filed 2015-04-14 | ||
| 2014-09-30 | $5.28K 10-Q · filed 2015-12-01 | $24.59K derived: sum of 2 quarters · filed 2015-12-01 | $43.68K 10-Q · filed 2015-12-01 | $53.22K derived: sum of 4 quarters · filed 2015-12-01 | ||
| 2014-06-30 | $19.30K 10-Q · filed 2015-08-19 | $38.40K 10-Q · filed 2015-08-19 | $47.94K derived: sum of 3 quarters · filed 2015-08-19 | $57.17K derived: sum of 4 quarters · filed 2015-08-19 | ||
| 2014-03-31 | $19.10K 10-Q · filed 2015-05-15 | $28.64K derived: sum of 2 quarters · filed 2015-05-15 | $37.86K derived: sum of 3 quarters · filed 2015-05-15 | $46.68K derived: sum of 4 quarters · filed 2015-05-15 | ||
| 2013-12-31 | $9.54K derived: 10-K 12 month − 10-Q 9 month · filed 2015-04-14 | $18.77K derived: sum of 2 quarters · filed 2015-04-14 | $27.58K derived: sum of 3 quarters · filed 2015-04-14 | $36.40K 10-K · filed 2015-04-14 | ||
| 2013-09-30 | $9.23K 10-Q · filed 2014-11-13 | $18.05K derived: sum of 2 quarters · filed 2014-11-13 | $26.87K 10-Q · filed 2014-11-13 | $41.06K derived: sum of 4 quarters · filed 2014-11-13 | ||
| 2013-06-30 | $8.82K 10-Q · filed 2014-08-19 | $17.64K 10-Q · filed 2014-08-19 | $31.84K derived: sum of 3 quarters · filed 2014-08-19 | $37.91K derived: sum of 4 quarters · filed 2014-08-19 | ||
| 2013-03-31 | $8.82K 10-Q · filed 2014-05-14 | $23.02K derived: sum of 2 quarters · filed 2014-05-14 | $29.09K derived: sum of 3 quarters · filed 2014-05-14 | $33.34K derived: sum of 4 quarters · filed 2014-05-14 | ||
| 2012-12-31 | $14.20K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-27 | $20.27K derived: sum of 2 quarters · filed 2014-03-27 | $24.52K derived: sum of 3 quarters · filed 2014-03-27 | $27.00K 10-K · filed 2014-03-27 | ||
| 2012-09-30 | $6.07K 10-Q · filed 2013-11-08 | $10.32K derived: sum of 2 quarters · filed 2013-11-08 | $12.80K 10-Q · filed 2013-11-08 | |||
| 2012-06-30 | $4.25K 10-Q/A · filed 2013-09-06 | $6.73K 10-Q/A · filed 2013-09-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |